Vriesendorp R - Search Results

1

Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.

van der Burg ME, ten Bokkel Huinink WW, Vriesendorp R, van Oosterom AT, Neijt JP, Vermorken JB, van Putten WL, Kooiman A. van der Burg ME, et al. Among authors: vriesendorp r. Eur J Cancer Clin Oncol. 1987 Jul;23(7):997-8. doi: 10.1016/0277-5379(87)90348-8. Eur J Cancer Clin Oncol. 1987. PMID: 3666002

2

Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5.

Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Vriesendorp R, Pinedo HM. Neijt JP, et al. Among authors: vriesendorp r. Radiother Oncol. 1984 Jun;2(1):19-29. doi: 10.1016/s0167-8140(84)80034-1. Radiother Oncol. 1984. PMID: 6438704

3

Five-year survival of patients with disseminated nonseminomatous testicular cancer treated with cisplatin, vinblastine, and bleomycin.

Stoter G, Vendrik CP, Struyvenberg A, Sleyfer DT, Vriesendorp R, Schraffordt Koops H, van Oosterom AT, ten Bokkel Huinink WW, Pinedo HM. Stoter G, et al. Among authors: vriesendorp r. Cancer. 1984 Oct 15;54(8):1521-4. doi: 10.1002/1097-0142(19841015)54:8<1521::aid-cncr2820540808>3.0.co;2-8. Cancer. 1984. PMID: 6206937

4

Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.

Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Vriesendorp R, Kooyman CD, van Lindert AC, Hamerlynck JV, van Lent M, van Houwelingen JC, et al. Neijt JP, et al. Among authors: vriesendorp r. Lancet. 1984 Sep 15;2(8403):594-600. doi: 10.1016/s0140-6736(84)90594-4. Lancet. 1984. PMID: 6147640 Clinical Trial.

5

High-dose teniposide for refractory malignancies: a phase I study.

de Vries EG, Mulder NH, Postmus PE, Vriesendorp R, Willemse PH, Sleijfer DT. de Vries EG, et al. Among authors: vriesendorp r. Cancer Treat Rep. 1986 May;70(5):595-8. Cancer Treat Rep. 1986. PMID: 3708608

6

Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study.

Postmus PE, de Vries EG, De Vries-Hospers HG, Vriesendorp R, van Imhoff GW, Holthuis JJ, Sibinga CT, Sleijfer DT, Mulder NH. Postmus PE, et al. Among authors: vriesendorp r. Eur J Cancer Clin Oncol. 1984 Jun;20(6):777-82. doi: 10.1016/0277-5379(84)90216-5. Eur J Cancer Clin Oncol. 1984. PMID: 6086355

7

Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin.

van der Meer J, de Vries EG, Vriesendorp R, Willemse PH, Donker AJ, Aalders JG. van der Meer J, et al. Among authors: vriesendorp r. J Cancer Res Clin Oncol. 1985;110(2):119-22. doi: 10.1007/BF00402723. J Cancer Res Clin Oncol. 1985. PMID: 2413037

8

High-dose etoposide for refractory malignancies: a phase I study.

Postmus PE, Mulder NH, Sleijfer DT, Meinesz AF, Vriesendorp R, de Vries EG. Postmus PE, et al. Among authors: vriesendorp r. Cancer Treat Rep. 1984 Dec;68(12):1471-4. Cancer Treat Rep. 1984. PMID: 6509453

9

Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer.

Vriesendorp R, Aalders JG, Sleijfer DT, Postmus PE, Willemse PH, Bouma J, Mulder NH. Vriesendorp R, et al. Gynecol Oncol. 1984 Mar;17(3):271-6. doi: 10.1016/0090-8258(84)90210-5. Gynecol Oncol. 1984. PMID: 6368331

10

Treatment of malignant germ cell tumors of the ovary with cisplatin, vinblastine, and bleomycin (PVB).

Vriesendorp R, Aalders JG, Sleijfer DT, Willemse PH, Bouma J, Mulder NH. Vriesendorp R, et al. Cancer Treat Rep. 1984 May;68(5):779-81. Cancer Treat Rep. 1984. PMID: 6202407

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters